Det nye forumet finner du her

Tilbake til: Farma og medisin
Innlegg av: Yzf R1 (13.05.18 21:40 ), lest 4478 ganger
Ticker: BIOTEC
Endret: 13.05.18 21:43

Phase II vaccine study indicate promising adjuvant SBG

Tromsø 13th May 2018) The ongoing vaccine study with Soluble Beta-Glucan (SBG®) from Biotec Pharmacon ("Biotec", OSE: BIOTEC) as an oral adjuvant shows very promising treatment effects in children with relapsed high-risk neuroblastoma. The immuno-oncology investigators in New York, interpret a promising adjuvant effect of SBG® on cancer vaccine. "The results (outlined below) offer further hope for children with Neuroblastoma. Additionally, this vaccine/SBG® treatment regime has an excellent safety profile with no observable side-effects", states Chief Scientific Officer, Rolf Engstad.